Ulka Vaishampayan

202 posts

Ulka Vaishampayan

Ulka Vaishampayan

@drulkav

Katılım Nisan 2023
335 Takip Edilen99 Takipçiler
Ulka Vaishampayan
Ulka Vaishampayan@drulkav·
Pls activate Swog 2419 the BIOFRONT trial. First large randomized trial testing combo of probiotic with immune therapy ( Ipi and nivo or Cabo and nivo or Len and pembro) in Frontline RCC @ esfeller
Laura Esfeller@LauraEsfeller

Finally, a clinical trial I’ve been working on for 2 years w/ @PBarataMD @drulkav @montypal @BrianShuch & many others @SWOG opens for enrollment very, very soon, and I couldn’t be more excited. S2419 (BIOFRONT) will be the first SWOG trial and the first phase III trial anywhere

English
0
0
0
100
Ulka Vaishampayan retweetledi
Kidney Cancer
Kidney Cancer@KidneyCancer·
🌉 #GU26 is in the books for team KCA! Ahead of #KidneyCancerAwarenessMonth, amazing to see the work advocates, researchers, and more are doing together to drive #kidneycancer science forward - proud to contribute to the efforts 🧡 So much for patients to be hopeful about!
Kidney Cancer tweet mediaKidney Cancer tweet mediaKidney Cancer tweet mediaKidney Cancer tweet media
English
0
5
36
2K
Ulka Vaishampayan
Ulka Vaishampayan@drulkav·
Commendable to help define response and continue advancement in MIBC
Andrea Necchi@AndreaNecchi

Happy to share a vision with my friend @UroDocAsh on our continuing efforts to optimize treatments and outcomes for patients with MIBC #bladdercancer #clinicalresearch @SanRaffaeleMI @MyUniSR @urotoday @IBCG_BladderCA @OncoAlert @ASCO #DailyNews Developing Clinical Complete Response Definitions for Muscle-Invasive Bladder Cancer dailynews.ascopubs.org/do/developing-…

English
0
0
0
42
Ulka Vaishampayan
Ulka Vaishampayan@drulkav·
Pls attend and derive benefit from this breakfast event on Feb 28 am of Asco GU symposium.
English
0
0
1
29
Ulka Vaishampayan retweetledi
Sameer Keole
Sameer Keole@SameerKeoleMD·
We’re launching this program to fill a key gap for our members. Radiation medicine physicians play a vital role in radiopharmaceutical delivery, and securing AU status is essential. We’ve been working hard to support them.
ASTRO@ASTRO_org

COMING SOON: ASTRO's Authorized User Training Program for RPT This is the newest training opportunity from ASTRO for physicians interested in becoming Authorized Users for radiopharmaceuticals. Supported by an educational grant from Novartis Pharmaceuticals Corporation. Learn more: ow.ly/SY6v50XBkrX

English
1
7
36
5.3K
Benjamin L Maughan
Benjamin L Maughan@maughanonc·
It’s official. Moving to UT San Antonio to lead their GU program. Also looking to recruit new GU medical oncologists—message me if interested to join a growing program. Great urologic oncology presence and history. Now let’s also make med onc history there together
English
31
4
136
13.7K
Ulka Vaishampayan
Ulka Vaishampayan@drulkav·
My thoughts on ESMO data Neoadjuvant enfortumab +pembro has an amazing 57% pCR rate and improved EFS and OS. However not compared to chemo. control arm is no systemic therapy. After pCR is post op therapy is needed. Can ctDNA be used as a guide?
English
0
0
1
88